Mild autonomous cortisol secretion (MACS) is associated with increased mortality in patients with adrenal adenomas only in the presence of type 2 diabetes: a retrospective cohort study
Main finding · MortalityResult — go to the resultHazard ratio 2.51 95% CI 1.41–4.48Authors' conclusion
Among patients with adrenal adenomas, MACS is related to increased CVD prevalence and is associated with mortality in patients with T2D.
Study context
- Participants
- 668 participants
- Exposure
- MACS vs non-functioning adrenal adenomas, with and without T2D
- Outcome
- Mortality
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Hazard ratio
2.51
95% CI 1.41–4.48
P < 0.01
MACS with T2Dvs NFAA without T2D
HR 2.51 (95% CI 1.41–4.48); P < 0.01
Observational data: associations, not effects.
Further findings
Baseline characteristics, T2D vs no T2D
- T2D: higher post 1 mg dexamethasone suppression test (DST) cortisol and more often hypertension, dyslipidemia and cardiovascular disease (CVD) vs no T2D
T2D cohort: MACS vs no hypercortisolism
- Elevation in CVD prevalence with MACS
- 3-fold
- Higher HbA1c with MACS
- No difference in age, sex, dyslipidemia, hypertension, BMI
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Mild autonomous cortisol secretion (MACS) is associated with increased mortality in patients with adrenal adenomas only in the presence of type 2 diabetes: a retrospective cohort study. Cardiovasc Diabetol. Published 22 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →